CTLA4 and non-small cell lung carcinoma: In contrast, a retrospective study of 205 NSCLC patients found that 19% experienced pneumonitis during PD-1/PD-L1 blockade (39), suggesting that CTLA-4 inhibitors may result in a lower incidence of pneumonitis compared to PD-1/PD-L1 inhibitors (40).